An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.
Expert opinion on pharmacotherapy(2023)
摘要
S1PR modulators decrease relapse rate and may modestly delay disease progression in people with relapsing MS. Aside their established benefit, their place and timing within the long-term DMT strategy in MS, as well as their immunological effects in the new and evolving context of the post-COVID-19 pandemic and vaccination campaigns warrant further study.
更多查看译文
关键词
Fingolimod,multiple sclerosis,ozanimod,ponesimod,siponimod,sphingosine 1-phosphate receptor modulators
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要